

# Guruprasad P Aithal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9059840/publications.pdf>

Version: 2024-02-01

227  
papers

17,596  
citations

22153  
59  
h-index

15266  
126  
g-index

232  
all docs

232  
docs citations

232  
times ranked

16073  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet</i> , The, 2016, 387, 679-690.	13.7	1,397
2	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. <i>Lancet</i> , The, 1999, 353, 717-719.	13.7	1,181
3	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <i>Nature Genetics</i> , 2009, 41, 816-819.	21.4	950
4	Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2008, 135, 1176-1184.	1.3	636
5	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019, 70, 1222-1261.	3.7	629
6	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. <i>Hepatology</i> , 2008, 47, 455-460.	7.3	625
7	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	7.3	528
8	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	12.8	478
9	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	1.3	412
10	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.	30.5	409
11	Drug-induced liver injury: recent advances in diagnosis and risk assessment. <i>Gut</i> , 2017, 66, 1154-1164.	12.1	370
12	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. <i>Gastroenterology</i> , 2019, 156, 2230-2241.e11.	1.3	346
13	Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 37-49.	0.9	338
14	Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes. <i>Gastroenterology</i> , 2007, 132, 272-281.	1.3	318
15	Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline â€” March 2017. <i>Endoscopy</i> , 2017, 49, 989-1006.	1.8	284
16	Guidelines on the management of ascites in cirrhosis. <i>Gut</i> , 2021, 70, 9-29.	12.1	280
17	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ†. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
18	Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline â€” Updated January 2017. <i>Endoscopy</i> , 2017, 49, 695-714.	1.8	270

#	ARTICLE	IF	CITATIONS
19	Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Updated August 2018. <i>Endoscopy</i> , 2019, 51, 179-193.	1.8	241
20	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	7.3	227
21	Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. <i>Hepatology</i> , 2004, 39, 1430-1440.	7.3	216
22	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
23	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	1.3	174
24	ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. <i>Hepatology</i> , 2019, 69, 1075-1086.	7.3	174
25	No Difference Between High-Fructose and High-Glucose Diets on Liver Triacylglycerol or Biochemistry in Healthy Overweight Men. <i>Gastroenterology</i> , 2013, 145, 1016-1025.e2.	1.3	162
26	Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: A general population-based study. <i>Journal of Hepatology</i> , 2008, 49, 732-738.	3.7	152
27	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
28	Nonsteroidal Anti-Inflammatory Drug–Induced Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2007, 11, 563-575.	2.1	139
29	Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 288-297.	8.1	138
30	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. <i>Journal of Hepatology</i> , 2010, 53, 1049-1053.	3.7	137
31	Hepatotoxicity related to antirheumatic drugs. <i>Nature Reviews Rheumatology</i> , 2011, 7, 139-150.	8.0	137
32	Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. <i>Journal of Hepatology</i> , 2000, 33, 949-952.	3.7	132
33	All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. <i>Liver International</i> , 2012, 32, 79-84.	3.9	125
34	Lower gut microbiome diversity and higher abundance of proinflammatory genus <i>Collinsella</i> are associated with biopsy-proven nonalcoholic steatohepatitis. <i>Gut Microbes</i> , 2020, 11, 569-580.	9.8	125
35	Accuracy of hepatic adverse drug reaction reporting in one English health region. <i>BMJ: British Medical Journal</i> , 1999, 319, 1541-1541.	2.3	121
36	Efficacy, Safety and Predictive Factors for a Positive Yield of EUS-Guided Trucut Biopsy: A Large Tertiary Referral Center Experience. <i>American Journal of Gastroenterology</i> , 2009, 104, 584-591.	0.4	110

#	ARTICLE	IF	CITATIONS
37	Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. <i>Gastrointestinal Endoscopy</i> , 2002, 55, 648-654.	1.0	109
38	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 784-795.	1.5	108
39	1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998–2009: A large population study. <i>Journal of Hepatology</i> , 2014, 60, 282-289.	3.7	107
40	Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 511-518.	5.7	105
41	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	3.7	104
42	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 103-111.	7.3	103
43	Genetic Basis of Drug-Induced Liver Injury: Present and Future. <i>Seminars in Liver Disease</i> , 2014, 34, 123-133.	3.6	101
44	A study of $T_1$ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. <i>NMR in Biomedicine</i> , 2015, 28, 706-714.	2.8	100
45	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. <i>Journal of Hepatology</i> , 2017, 67, 137-144.	3.7	100
46	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	1.3	97
47	Fracture Risk in People With Primary Biliary Cirrhosis: A Population-Based Cohort Study. <i>Gastroenterology</i> , 2006, 131, 1752-1757.	1.3	89
48	Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 685-686.	3.7	88
49	Upstream and coding region CYP2C9 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 813-822.	5.7	87
50	Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. <i>Journal of Hepatology</i> , 2016, 65, 1131-1139.	3.7	87
51	Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. <i>BMJ Open</i> , 2015, 5, e007516-e007516.	1.9	86
52	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	4.4	80
53	Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study. <i>Hepatology</i> , 2007, 46, 1131-1137.	7.3	76
54	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020, 72, 88-102.	7.3	76

#	ARTICLE	IF	CITATIONS
55	Natural history of histologically proven alcohol-related liver disease: A systematic review. <i>Journal of Hepatology</i> , 2019, 71, 586-593.	3.7	72
56	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
57	Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. <i>Journal of Hepatology</i> , 2021, 75, 935-959.	3.7	66
58	HLA-DRB1*16. Pharmacogenetics and Genomics, 2016, 26, 218-224.	1.5	63
59	Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. <i>Liver International</i> , 2015, 35, 1801-1808.	3.9	62
60	Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. <i>Journal of Hepatology</i> , 2018, 69, 948-957.	3.7	62
61	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. <i>Hepatology International</i> , 2021, 15, 258-282.	4.2	62
62	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	4.7	58
63	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1079-1086.	1.9	56
64	A role for the pregnane X receptor in flucloxacillin-induced liver injury. <i>Hepatology</i> , 2010, 51, 1656-1664.	7.3	55
65	Polygenic architecture informs potential vulnerability to drug-induced liver injury. <i>Nature Medicine</i> , 2020, 26, 1541-1548.	30.7	55
66	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021, 73, 1920-1931.	7.3	54
67	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	3.7	54
68	Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. <i>Lancet</i> , 2020, 395, 226-239.	13.7	53
69	Risk of Cardiovascular and Cerebrovascular Events in Primary Biliary Cirrhosis: A Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2784-2788.	0.4	52
70	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	4.7	52
71	A revised electronic version of RUCAM for the diagnosis of DILI. <i>Hepatology</i> , 2022, 76, 18-31.	7.3	52
72	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. <i>BMJ Open</i> , 2017, 7, e015659.	1.9	50

#	ARTICLE	IF	CITATIONS
73	The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men. <i>Applied Physiology, Nutrition and Metabolism</i> , 2018, 43, 482-490.	1.9	49
74	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 504-515.	3.7	49
75	Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1185-1194.	4.7	49
76	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. <i>Journal of Hepatology</i> , 2020, 73, 231-240.	3.7	49
77	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from a Drug Acyl Glucuronide Metabolite: Multiple Albumin Adductions in Diclofenac Patients. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 387-402.	2.5	47
78	Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 395-409.	3.3	47
79	Accuracy of EUS for detection of intraductal papillary mucinous tumor of the pancreas. <i>Gastrointestinal Endoscopy</i> , 2002, 56, 701-707.	1.0	47
80	Causality Assessment for Suspected DILI During Clinical Phases of Drug Development. <i>Drug Safety</i> , 2014, 37, 47-56.	3.2	45
81	Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 519-523.	2.4	43
82	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021, 73, 268-281.	7.3	43
83	Monitoring Liver Function during Methotrexate Therapy for Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 357-363.	6.7	42
84	The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 451, 943-948.	2.8	42
85	Increased liver fat and glycogen stores after consumption of high versus low glycaemic index food: A randomized crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 70-77.	4.4	42
86	Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1520-1525.	2.3	41
87	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847.	12.4	40
88	Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2330-2338.e1.	4.4	39
89	Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. <i>Journal of Hepatology</i> , 2018, 69, 1015-1024.	3.7	38
90	Multicenter experience from the UK and Ireland of use of lumen-apposing metal stent for transluminal drainage of pancreatic fluid collections. <i>Endoscopy International Open</i> , 2018, 06, E259-E265.	1.8	37

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. <i>Gut</i> , 2022, 71, 254-264.	12.1	37
92	Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. <i>Hepatology</i> , 2014, 60, 158-168.	7.3	35
93	Effect of exercise intensity on circulating hepatokine concentrations in healthy men. <i>Applied Physiology, Nutrition and Metabolism</i> , 2019, 44, 1065-1072.	1.9	35
94	Efficacy of Recombinant Human Interleukin-10 in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Subjects With Increased Risk. <i>Pancreas</i> , 2009, 38, 267-274.	1.1	33
95	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	3.7	33
96	Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2019, 114, 1744-1752.	0.4	32
97	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	4.7	31
98	Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. <i>Liver International</i> , 2021, 41, 1565-1575.	3.9	31
99	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404.	7.1	29
100	Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. <i>JHEP Reports</i> , 2021, 3, 100232.	4.9	29
101	How to tackle rising rates of liver disease in the UK. <i>BMJ</i> , The, 2013, 346, f807-f807.	6.0	27
102	Acute Hyperenergetic, High-Fat Feeding Increases Circulating FGF21, LECT2, and Fetuin-A in Healthy Men. <i>Journal of Nutrition</i> , 2020, 150, 1076-1085.	2.9	27
103	EUS-guided Trucut mural biopsies in the investigation of unexplained thickening of the esophagogastric wall. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 624-629.	1.0	26
104	Preempting and preventing drug-induced liver injury. <i>Nature Genetics</i> , 2010, 42, 650-651.	21.4	25
105	EUS-guided choledochoduodenostomy with electrocautery-enhanced lumen-apposing metal stents in patients with malignant distal biliary obstruction: multicenter collaboration from the United Kingdom and Ireland. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 432-442.	1.0	25
106	CYP2C9 polymorphism and warfarin dose requirements. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 408-409.	2.4	24
107	Genetic Regulation of Warfarin Metabolism and Response. <i>Seminars in Vascular Medicine</i> , 2003, 03, 231-238.	2.1	24
108	The Utility of Scoring Systems in Predicting Early and Late Mortality in Alcoholic Hepatitis: Whose Score Is It Anyway?. <i>International Journal of Hepatology</i> , 2012, 2012, 1-5.	1.1	24



#	ARTICLE	IF	CITATIONS
109	Dynamics of 5-carboxylcytosine during hepatic differentiation: Potential general role for active demethylation by DNA repair in lineage specification. <i>Epigenetics</i> , 2017, 12, 277-286.	2.7	24
110	Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort. <i>BMJ Open</i> , 2019, 9, e027244.	1.9	24
111	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , 2021, 74, 972-974.	3.7	24
112	Diagnosis, presentation and initial severity of Autoimmune Hepatitis (<scp>AIH</scp>) in patients attending 28 hospitals in the <scp>UK</scp>. <i>Liver International</i> , 2018, 38, 1686-1695.	3.9	23
113	Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 515-521.	0.9	23
114	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. <i>Journal of Hepatology</i> , 2021, 75, 333-341.	3.7	23
115	The role of hepatic lipid composition in obesity-related metabolic disease. <i>Liver International</i> , 2021, 41, 2819-2835.	3.9	23
116	Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. <i>Photodiagnosis and Photodynamic Therapy</i> , 2012, 9, 287-292.	2.6	22
117	Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: <scp>R</scp>esults of a randomized controlled trial using 2 dietary approaches. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1179-1183.	4.4	22
118	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , 2017, 8, 252-259.	1.8	22
119	Glycaemic, gastrointestinal, hormonal and appetitive responses to pearl millet or oats porridge breakfasts: a randomised, crossover trial in healthy humans. <i>British Journal of Nutrition</i> , 2019, 122, 1142-1154.	2.3	21
120	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 1920.	3.2	21
121	Warfarin dose requirement and CYP2C9 polymorphisms. <i>Lancet</i> , The, 1999, 353, 1972-1973.	13.7	20
122	Dangerous liaisons: Drug, host and the environment. <i>Journal of Hepatology</i> , 2007, 46, 995-998.	3.7	20
123	Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk.. <i>EClinicalMedicine</i> , 2021, 34, 100835.	7.1	20
124	Efficacy, Safety, and Predictive Factors for a Positive Yield of EUS-Guided Trucut Biopsy. <i>American Journal of Gastroenterology</i> , 2009, 104, 584-591.	0.4	20
125	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
126	Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study. <i>Journal of Gastroenterology</i> , 2017, 52, 1192-1200.	5.1	19



#	ARTICLE	IF	CITATIONS
127	Glycaemic, gastrointestinal and appetite responses to breakfast porridges from ancient cereal grains: A MRI pilot study in healthy humans. Food Research International, 2019, 118, 49-57.	6.2	19
128	Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis. Seminars in Liver Disease, 2015, 35, 421-431.	3.6	18
129	Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans. Toxicological Sciences, 2021, 181, 23-34.	3.1	18
130	Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis. JHEP Reports, 2021, 3, 100317.	4.9	18
131	HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology, 2022, 166, 68-77.	4.4	18
132	HLA associations with infliximab-induced liver injury. Pharmacogenomics Journal, 2020, 20, 681-686.	2.0	17
133	What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology, 2021, 60, 5785-5794.	1.9	17
134	Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. Scandinavian Journal of Gastroenterology, 2017, 52, 107-115.	1.5	15
135	Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease. European Journal of Applied Physiology, 2018, 118, 817-828.	2.5	15
136	Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage. European Journal of Gastroenterology and Hepatology, 2013, 25, 201-207.	1.6	14
137	Immune dysfunction in patients with obstructive jaundice before and after endoscopic retrograde cholangiopancreatography. Clinical Science, 2016, 130, 1535-1544.	4.3	14
138	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	1.7	13
139	Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology and Therapeutics, 2020, 51, 1188-1197.	3.7	13
140	When is a herb a drug?. European Journal of Gastroenterology and Hepatology, 2005, 17, 391-393.	1.6	12
141	Zanubrutinib-induced liver injury: a case report and literature review. BMC Gastroenterology, 2021, 21, 244.	2.0	12
142	Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial. Alimentary Pharmacology and Therapeutics, 2022, 55, 1297-1310.	3.7	12
143	Hepatotoxicity Related to Methotrexate. , 2013, , 593-604.		11
144	The effect of exercise training on adipose tissue insulin sensitivity: A systematic review and meta-analysis. Obesity Reviews, 2022, 23, e13445.	6.5	11

#	ARTICLE	IF	CITATIONS
145	The detection of oesophageal varices using a novel, disposable, probe-based transnasal endoscope: a prospective diagnostic pilot study. Liver International, 2016, 36, 1639-1648.	3.9	10
146	Using MRI to study the alterations in liver blood flow, perfusion, and oxygenation in response to physiological stress challenges: Meal, hyperoxia, and hypercapnia. Journal of Magnetic Resonance Imaging, 2019, 49, 1577-1586.	3.4	10
147	Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav. DNA and Cell Biology, 2020, 39, 349-354.	1.9	10
148	Validation of the AASLD recommendations for classification of oesophageal varices in clinical practice. Liver International, 2020, 40, 905-912.	3.9	10
149	Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video). Gastrointestinal Endoscopy, 2021, 94, 321-328.	1.0	10
150	Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1327-1343.	3.3	10
151	Diffuse nesidioblastosis causing hyperinsulinemic hypoglycemia: the importance of pancreatic sampling on EUS. Gastrointestinal Endoscopy, 2008, 68, 571-572.	1.0	9
152	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. Toxicology, 2008, 253, 10.	4.2	8
153	Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 123-130.	3.7	8
154	The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study. Alcohol and Alcoholism, 2022, 57, 203-210.	1.6	8
155	The performance of transient elastography compared to clinical acumen and routine tests – what is the incremental diagnostic value?. Liver International, 2013, 33, 172-179.	3.9	7
156	Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine. Digestive Diseases, 2017, 35, 314-322.	1.9	7
157	MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability. Journal of Magnetic Resonance Imaging, 2021, 53, 1422-1431.	3.4	7
158	Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy. Journal of Clinical Medicine, 2021, 10, 632.	2.4	7
159	Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver International, 2022, 42, 628-639.	3.9	7
160	Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. World Journal of Hepatology, 2022, 14, 1025-1037.	2.0	7
161	Defining “acute on chronic liver failure”: an identity crisis!. Indian Journal of Gastroenterology, 2010, 29, 177-180.	1.4	6
162	Incidence of Post-ERCP Pancreatitis From Direct Pancreatic Juice Collection in Hereditary Pancreatitis and Familial Pancreatic Cancer Before and After the Introduction of Prophylactic Pancreatic Stents and Rectal Diclofenac. Pancreas, 2015, 44, 260-265.	1.1	6

#	ARTICLE	IF	CITATIONS
163	The Evaluation and Use of a Food Frequency Questionnaire Among the Population in Trivandrum, South Kerala, India. <i>Nutrients</i> , 2020, 12, 383.	4.1	6
164	ÂMonozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?. <i>Annals of Hepatology</i> , 2016, 15, 277-82.	1.5	6
165	The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. <i>United European Gastroenterology Journal</i> , 2018, 6, 1372-1379.	3.8	5
166	Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation. <i>BMJ Open</i> , 2020, 10, e041574.	1.9	5
167	Validation of the <scp>aMAP</scp> score to predict hepatocellular carcinoma development in a cohort of alcoholâ€related cirrhosis patients. <i>Liver Cancer International</i> , 2022, 3, 99-104.	1.3	5
168	Jaundice: applying lessons from physiology. <i>Surgery</i> , 2009, 27, 11-18.	0.3	4
169	Mind the Gap. <i>ATLA Alternatives To Laboratory Animals</i> , 2010, 38, 1-4.	1.0	4
170	Immune-Mediated Drug-Induced Liver Injury. , 2014, , 401-412.		4
171	PS-112-Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes. <i>Journal of Hepatology</i> , 2019, 70, e70-e71.	3.7	4
172	Of Potions, Poisons, Polygonum, and Preâ€emptive Polymorphism. <i>Hepatology</i> , 2019, 70, 8-10.	7.3	4
173	Effect of Intake of Food Hydrocolloids of Bacterial Origin on the Glycemic Response in Humans: Systematic Review and Narrative Synthesis. <i>Nutrients</i> , 2021, 13, 2407.	4.1	4
174	Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000641.	2.7	4
175	Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home. <i>Clinical Medicine</i> , 2021, 21, e32-e38.	1.9	4
176	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. <i>Rheumatology</i> , 2022, 61, 2783-2791.	1.9	4
177	Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. <i>Biomedicines</i> , 2022, 10, 477.	3.2	4
178	Treatment and outcome of autoimmune hepatitis: Audit of 28 <scp>UK</scp> centres. <i>Liver International</i> , 2022, 42, 1571-1584.	3.9	4
179	Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 215, 19-29.	1.7	4
180	Concurrent mucinous cystadenoma of the liver and bile duct: a rare cause of jaundice. <i>Gastrointestinal Endoscopy</i> , 2006, 63, 870-872.	1.0	3

#	ARTICLE	IF	CITATIONS
181	Drug-induced liver injury. <i>Medicine</i> , 2015, 43, 590-593.	0.4	3
182	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. <i>Annals of Internal Medicine</i> , 2017, 166, 229.	3.9	3
183	Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. <i>Gastroenterology</i> , 2018, 154, 1848-1850.	1.3	3
184	Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan). <i>Gastrointestinal Nursing</i> , 2018, 16, S15-S22.	0.1	3
185	Value of FIB-4 and NAFLD fibrosis scores for screening of liver fibrosis in the general population. <i>Journal of Hepatology</i> , 2020, 73, S414-S415.	3.7	3
186	Pro-adrenomedullin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 606-614.	1.5	3
187	Estimating the clinical prevalence of Wilson's disease in the UK. <i>JHEP Reports</i> , 2021, 3, 100329.	4.9	3
188	Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis. <i>PLoS ONE</i> , 2022, 17, e0268034.	2.5	3
189	Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study. <i>Nutrients</i> , 2022, 14, 2808.	4.1	3
190	Steering azathioprine safely: lessons from pharmacogenetics Cuffari C, Hunt S, Bayless T, Utilisation of Erythrocyte 6-Thioguanine Metabolite Levels to Optimise Azathioprine Therapy in Patients With Inflammatory Bowel Disease, <i>Gut</i> 2001;48:642-6. <i>American Journal of Gastroenterology</i> , 2001, 96, 3202-3203.	0.4	2
191	Portal hypertension and ascites. <i>Surgery</i> , 2007, 25, 28-33.	0.3	2
192	Jaundice: applying lessons from physiology. <i>Surgery</i> , 2011, 29, 603-609.	0.3	2
193	Analysis of genotyping for predicting liver injury marker, procollagen $\alpha 1(I)$ in persons at risk of non-alcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 1832-1838.	3.9	2
194	FRI-231-Hostel-based models can improve the engagement of homeless individuals with liver services: VALID (vulnerable adults liver disease) study. <i>Journal of Hepatology</i> , 2019, 70, e496-e497.	3.7	2
195	Drug-induced liver injury. <i>Medicine</i> , 2019, 47, 734-739.	0.4	2
196	PS-098-Prevalence and risk factors of first line anti-tuberculosis drug induced liver injury: Large cohort study involving 4652 patients. <i>Journal of Hepatology</i> , 2019, 70, e62-e63.	3.7	2
197	Editorial: treating hepatorenal syndrome—a window and the views. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 895-896.	3.7	2
198	Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH). <i>Frontline Gastroenterology</i> , 2022, 13, flgastro-2020-101661.	1.8	2

#	ARTICLE	IF	CITATIONS
199	Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation. <i>BMJ Open</i> , 2021, 11, e045802.	1.9	2
200	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-54.	0.7	2
201	Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.7	2
202	Jaundice: applying lessons from physiology. <i>Surgery</i> , 2014, 32, 627-634.	0.3	1
203	Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?" <i>Journal of Hepatology</i> , 2019, 70, 213-214.	3.7	1
204	Gut Microbial Profile Is Associated With Residential Settings and Not Nutritional Status in Adults in Karnataka, India. <i>Frontiers in Nutrition</i> , 2021, 8, 595756.	3.7	1
205	Large volume paracentesis: to do or where to do?. <i>Gut</i> , 2021, 70, gutjnl-2021-324249.	12.1	1
206	Hepatic ADRs. , 0, , 429-443.		1
207	Hepatic Adverse Drug Reactions. , 0, , 459-474.		0
208	Dyspnoea in a patient with cirrhosis. <i>Gut</i> , 2009, 58, 156-156.	12.1	0
209	Portal hypertension and ascites. <i>Surgery</i> , 2010, 28, 234-240.	0.3	0
210	Portal hypertension and ascites. <i>Surgery</i> , 2011, 29, 640-646.	0.3	0
211	To feed or what to feed in cirrhosis?. <i>Hepatology</i> , 2012, 56, 1590-1590.	7.3	0
212	Portal hypertension and ascites. <i>Surgery</i> , 2014, 32, 661-667.	0.3	0
213	Drug-Induced Cholestasis: Mechanisms and Importance. , 2017, , 117-128.		0
214	Magnetic Resonance Imaging Methods for Assessing Cirrhosis and Portal Hypertension. , 2018, , 211-223.		0
215	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S20-S21.	3.7	0
216	Hepatocyte-specific deficiency of sphingosine kinase 1 exacerbates acetaminophen-induced liver injury. <i>Journal of Hepatology</i> , 2020, 73, S131-S132.	3.7	0

#	ARTICLE	IF	CITATIONS
217	Diagnostic accuracy of magnetic resonance elastography for the staging of fibrosis and diagnosis of steatohepatitis in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology, 2020, 73, S411.	3.7	0
218	Etiology and diagnosis of ascites: contemporary cohort study in a secondary care setting. Journal of Hepatology, 2020, 73, S764.	3.7	0
219	Commentary: non-alcoholic steatohepatitisâ€”finding and minding the fire behind the smoke. Alimentary Pharmacology and Therapeutics, 2020, 51, 209-211.	3.7	0
220	ID: 3502884 ENDOSCOPIC ULTRASOUND GUIDED CHOLEDOCHODUODENOSTOMY WITH ELECTROCAUTERY ENHANCED LUMEN APPOSING METAL STENTS IN THE TREATMENT OF MALIGNANT DISTAL BILIARY OBSTRUCTION: MULTI-CENTRE COLLABORATION FROM THE UK AND IRELAND. Gastrointestinal Endoscopy, 2021, 93, AB266.	1.0	0
221	Midodrine and the Ladder of Evidence to Climb. Journal of Clinical and Experimental Hepatology, 2021, 11, 528-530.	0.9	0
222	P-33 EVALUATION OF CIRCULATING METABOLOME IN THE SEARCH OF POTENTIAL DRUG-INDUCED LIVER INJURY BIOMARKERS. Annals of Hepatology, 2021, 24, 100397.	1.5	0
223	Pharmacogenetics in Gastroenterology. , 2006, , 273-294.		0
224	Immune-Mediated Drug-Induced Liver Injury. , 2020, , 491-504.		0
225	OTU-13â€¦Eus choledochoduodenostomy in malignant distal biliary obstruction: multi-centre collaboration from the UK and Ireland. , 2021, , .		0
226	Comparison of the reverse bevel versus Franseen type endoscopic ultrasound needle. World Journal of Gastrointestinal Endoscopy, 2020, 12, 266-275.	1.2	0
227	The Effects of Adding Gellan Gum to White Rice on the Glycemic, Gastrointestinal and Appetitive Responses: A Randomised, Controlled, Crossover Study. Current Developments in Nutrition, 2022, 6, 501.	0.3	0